Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop.
26 May 20